Health technology reassessment in the Brazilian public health system: Analysis of the current status-Reference-Cited by-同舟云学术

Health technology reassessment in the Brazilian public health system: Analysis of the current status

Published:2019-07-29 Issue:7 Volume:14 Page:e0220131
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Pereira Viviane Cássia^ORCID,Barreto Jorge Otávio Maia^ORCID,Neves Francisco Assis da Rocha

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference44 articles.

1. Transferability of National Institute for Health and Clinical Excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries;Z Kaló;Eur J Cancer Care (Engl),2012

2. ISPEP group of the French National Authority for Health. The public health benefit of medicines: how it has been assessed in France? The principles and results of five years’ experience;P Maison;Health Policy,2013

3. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care;RJ Kelly;Lancet Oncol,2014

4. IBGE—Instituto Brasileiro de Geografia e Estatística. Conta-satélite de saúde: Brasil: 2010-2015/IBGE [Internet]. Rio de Janeiro, 2017. https://biblioteca.ibge.gov.br/visualizacao/livros/liv101437.pdf. Accessed 12 Dec 2017.

5. From efficacy to equity: Literature review of decision criteria for resource allocation and healthcare decisionmaking;LA Guindo;Cost Eff Resour Alloc,2012

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Critical Intersect of Regulations, Health Technology Assessment, and Drug Safety Assessments;Drug Safety;2023-12-19

2. A Conceptual Framework for Life-Cycle Health Technology Assessment;Value in Health;2022-07

3. A indústria farmacêutica interfere na sustentabilidade do sistema de saúde pública no Brasil? Uma reflexão sobre a pressão por incorporação de medicamentos;Cadernos de Saúde Pública;2022

4. Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise;Current Oncology;2021-11-12

5. Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group;Current Oncology;2021-10-16